Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (%C4%8Cufer Tanja) .

171 - 180 / 387
First pagePrevious page14151617181920212223Next pageLast page
171.
172.
Kako premagati izgubo las
Marija Velepič, Jožica Bostič-Pavlovič, Helena Drolc, Tanja Čufer, 1993, other monographs and other completed works

Keywords: rak (medicina), bolniki, kemoterapija, radioterapija, izpadanje las, nasveti
Published in DiRROS: 29.04.2021; Views: 1038; Downloads: 324
.pdf Full text (3,38 MB)

173.
Kako olajšamo težave ob zdravljenju s kemoterapijo
Marija Velepič, Jožica Bostič-Pavlovič, Helena Drolc, Tanja Čufer, 1993, dictionary, encyclopaedia, lexicon, manual, atlas, map

Keywords: rak (medicina), kemoterapija, bolniki, nasveti
Published in DiRROS: 29.04.2021; Views: 1006; Downloads: 315
.pdf Full text (2,68 MB)

174.
175.
176.
Pot za uvajanje novih organiziranih presejalnih programov na državni ravni
Urška Ivanuš, Branko Zakotnik, Tanja Mate, Tina Bregant, 2020, published professional conference contribution

Keywords: onkologija, presejalni programi, javno zdravstvo, obvladovanje raka
Published in DiRROS: 08.04.2021; Views: 977; Downloads: 291
.pdf Full text (83,93 KB)

177.
Pogled onkologa
Tanja Ovčariček, 2020, independent professional component part or a chapter in a monograph

Keywords: onkologija, nefrologija, protitrombotično zdravljenje
Published in DiRROS: 06.04.2021; Views: 980; Downloads: 277
.pdf Full text (40,61 KB)

178.
Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma : an international multicenter study
Luka Brčić, Thomas Klikovits, Zsolt Megyesfalvi, Berta Mosleh, Katharina Sinn, Richard Hritcu, Viktoria Laszlo, Tanja Čufer, Aleš Rozman, Izidor Kern, Katja Mohorčič, 2021, original scientific article

Abstract: Background: Programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) immune-checkpoint blockade is a promising new therapeutic strategy in cancer. However, expression patterns and prognostic significance of PD-L1 and PD-1 are still controversial in human malignant pleural mesothelioma (MPM). Methods: Formalin-fixed paraffin-embedded (FFPE) tumor samples from 203 MPM patients receiving standard treatment without immunotherapy were collected from 5 European centers. PD-L1 and PD-1 expression of tumor cells (TCs) and tumor-infiltrating lymphocytes (TILs) were measured by immunohistochemistry and correlated with clinical parameters and long-term outcome. Results: High (>10%) PD-L1 TC and PD-1 TILs expressions were found in 18 (8%) and 39 (24%) patients, respectively. PD-L1 was rarely expressed by TILs [>/=1%, n=13 (8%); >10%, n=1]. No significant associations were found between the PD-L1 or PD-1 expression of TCs or TILs and clinicopathological parameters such as stage or histological subtype. Notably, patients with high (>10%) TC-specific PD-L1 expression exhibited significantly worse median overall survival (OS) (6.3 vs. 15.1 months of those with low TC PD-L1 expression; HR: 2.51, P<0.001). In multivariate cox regression analysis adjusted for clinical parameters, high TC PD-L1 expression (>10%) proved to be an independent negative prognostic factor for OS (HR: 2.486, P=0.005). There was no significant correlation between PD-L1 or PD-1 expression of TILs and OS. Conclusions: In this multicenter cohort study, we demonstrate that high (>10%) PD-L1 expression of TCs independently predicts worse OS in MPM. Further studies are warranted to investigate the value of PD-L1/PD-1 expression as a marker for treatment response in MPM patients receiving immunotherapy.
Keywords: mesothelioma - anatomy and histology - analysis, 1malignant pleural mesothelioma, programmed death-ligand 1, programmed cell death 1, PD-L1
Published in DiRROS: 31.03.2021; Views: 1287; Downloads: 554
URL Link to file

179.
Pogledi bolnikov in onkologov na uvajanje telemedicine v času epidemije covid-19
Miha Oražem, Irena Oblak, Tanja Španić, Ivica Ratoša, 2020, original scientific article

Abstract: Izhodišča: Pandemija koronavirusne bolezni 2019 (covid-19) je zaradi epidemioloških ukrepov, zlasti spodbujanja fizične distance, marsikje po svetu pospešila uvajanje telemedicine v klinično prakso. Zato smo želeli pridobiti stališča onkoloških bolnikov in zdravnikov do tovrstne obravnave v onkologiji. Metode: K izpolnjevanju dveh ločenih kvantitativnih vprašal-nikov smo med 27. majem in 11. junijem 2020 prek elektronske pošte ter s pomočjo Slovenskega združenja organizacij bolnikov z rakom (ONKO NET) povabili bolnike z rakom, ki so bili bodisi na aktivnem zdravljenju bodisi na sledenju po zaključenem zdravljenju, in zdravnike onkologe. Dodatno je bil v Sektorju radioterapije Onkološkega inštituta Ljubljana izveden presečni dan za bolnike med obsevanjem. Rezultati: Na spletni ali natisnjen vprašalnik za bolnike je odgovorilo 475 bolnikov, od tega 310 (65,3 %) na aktivnem onko-loškem zdravljenju in 132 (27,8 %) v fazi sledenja. Skoraj polovica bolnikov (48,4 %) je kot primarno diagnozo navedla rak dojk. Več kot desetina vseh (11,3 %) je zaradi pandemije želela opustiti zdravniški pregled. V zasebnem življenju jih pametni telefon ali tablico uporablja 72,4 % in vsaj 30 % bolnikov bi bilo pripravlje-nih v bodoče pogosteje uporabljati telemedicinske storitve. Od 168 povabljenih zdravnikov jih je na vprašalnik odgovoril 101 (60 %) in ocenil, da bi s pomočjo telemedicine lahko opravil 21 % (0%80 %) vseh svojih storitev. Če bi se sami znašli v vlogi bolnika, bi bila prip-ravljena po telemedicini poseči dobra polovica sodelujočih (54,5 %). Zaključki: Uporaba telemedicine v onkologiji bi bila ob upošteva-nju nekaterih omejitev sprejemljiva za pomemben del bolnikov in zdravnikov
Keywords: telemedicina, covid-19, onkologija
Published in DiRROS: 18.03.2021; Views: 1633; Downloads: 437
.pdf Full text (272,20 KB)

180.
Search done in 0.29 sec.
Back to top